Enlivex Therapeutics, a clinical-stage macrophage reprogramming immunotherapy company, announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application (number 201680029277.4) covering Allocetra, the Company’s immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection in China, with respect to methods, uses and pharmaceutical compositions for Allocetra. The company expects that this new patent will be issued in China in the coming months.Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, Covid-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.
